An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
AN2 Therapeutics to Present at Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
AN2 Therapeutics, Inc. (Nasdaq: ANTX) will participate in two upcoming investor conferences in November. Eric Easom, Co-Founder, President and CEO, will provide a corporate overview at the Stifel 2023 Healthcare Conference on November 15 at 3:00 p.m. ET and at the 6th Annual Evercore ISI HealthCONx Conference on November 29 at 8:45 a.m. ET. The presentations can be accessed on the AN2 Therapeutics website.
Positive
None.
Negative
None.
MENLO PARK, Calif.--(BUSINESS WIRE)--
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that company management will participate in two upcoming investor conferences in November.
Stifel 2023 Healthcare Conference
Eric Easom, Co-Founder, President and CEO will provide a corporate overview on Wednesday, November 15 at 3:00 p.m. ET.
6th Annual Evercore ISI HealthCONx Conference
Eric Easom, Co-Founder, President and CEO will provide a corporate overview on Wednesday, November 29 at 8:45 a.m. ET.
A webcast of the presentations can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com. An archived replay will be available for at least 30 days following the presentation.
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Our initial candidate is epetraborole, which we are studying as a once-daily, oral treatment with a novel mechanism of action for patients with nontuberculous mycobacteria (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, that leads to irreversible lung damage and can be fatal. For more information, please visit our website at www.an2therapeutics.com.
Which investor conferences will AN2 Therapeutics participate in November?
AN2 Therapeutics will participate in the Stifel 2023 Healthcare Conference on November 15 and the 6th Annual Evercore ISI HealthCONx Conference on November 29.
Who will provide the corporate overview at the investor conferences?
Eric Easom, Co-Founder, President and CEO of AN2 Therapeutics, will provide the corporate overview at both investor conferences.
Where can the presentations be accessed?
The presentations can be accessed on the Investors section of the AN2 Therapeutics website at www.an2therapeutics.com.
Will there be an archived replay of the presentations?
Yes, an archived replay of the presentations will be available for at least 30 days following the presentation.
an2 therapeutics, inc. is a california-based global health biopharmaceutical company focused on bringing the power of modern biomedical and drug development expertise to provide transformational medicines for patients suffering from infectious diseases. an2 is a mission-driven company, with a vision for humanity to be free from the threat of infectious diseases by addressing the urgent need for new treatments that can save lives across the globe. founded by a small team of biopharmaceutical industry leaders with a passion for global health and experience in infectious disease drug r&d, we strive to bring patients treatments that will restore their health and enable them to live productive lives.
